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Functional and morphological alterations of the intestinal epithelial barrier (IEB) have been consistently reported in
digestive disorders such as irritable bowel syndrome and inflammatory bowel disease. There is mounting evidence
that Parkinson’s disease (PD) is not only a brain disease but also a digestive disorder. Gastrointestinal involvement is
a frequent and early event in the course of PD, and it may be critically involved in the early development of the
disease. We therefore undertook the present survey to investigate whether changes in the IEB function and/or
morphology occur in PD. Colonic biopsies were performed in 31 PD patients and 11 age-matched healthy controls.
The para- and transcellular permeability were evaluated by measuring sulfonic acid and horseradish peroxidase flux
respectively, in colonic biopsies mounted in Ussing chambers. The expression and localization of the two tight
junctions proteins ZO-1 and occludin were analyzed by Western blot and immunofluorescence, respectively. The
para- and transcellular permeability were not different between PD patients and controls. The expression of occludin,
but not ZO-1, was significantly lower in colonic samples from PD patients as compared to controls and the cellular
distribution of both proteins was altered in colonic mucosal specimens from PD patients. Our findings provide
evidence that the IEB is morphologically altered in PD and further reinforce the potential role of the gastrointestinal
tract in the initiation and/or the progression of the disease.
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The intestinal epithelium forms a regulated barrier, known
as intestinal epithelial barrier (IEB), between the blood cir-
culation and the contents of the intestinal lumen [1]. It
prevents the passage of noxious contents while allowing
the absorption and secretion of nutrients [1]. Penetration
of this barrier occurs via two routes, either between epi-
thelial cells via the paracellular pathway, or through epi-
thelial cell via the transcellular pathway [1]. Among the
most important structures of the intestinal barrier are the
epithelial tight junctions (TJs) that connect adjacent enter-
ocytes together to determine paracellular permeability
through the lateral intercellular space [2]. They are formed
by transmembrane proteins such as claudins and occlu-
dins connected to the actin cytoskeleton via high* Correspondence: derkinderenp@yahoo.fr
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unless otherwise stated.molecular weight proteins called zona occludens (ZO-1,
ZO-2 and 3) [2]. Increased permeability of the IEB along
with changes in the expression levels of TJs proteins have
been consistently reported in several digestive disorders
such as inflammatory bowel disease [3,4] and irritable
bowel syndrome [5,6].
It has become evident over the last 20 years that PD is
a gut disorder (reviewed in [7]). Gastrointestinal symp-
toms occur in almost every PD patient at some point
and are among the most debilitating non-motor features
of the disease [8]. These clinical data have been supported
by post mortem studies that demonstrated the presence of
Lewy bodies and neurites in the enteric neurons in nearly
every case examined pathologically [9,10]. The German
pathologist Heiko Braak suggested that the appearance of
Lewy pathology in enteric neurons develop early in the
course of disease, prior to the involvement of the central
nervous system [11]. This led him to suggest that the
gastrointestinal tract might be a portal of entry for a puta-
tive pathogen that would breach the IEB to induce thentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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neurons [11].
The high prevalence of gastrointestinal symptoms and
pathology in PD and the possible derangement of gastro-
intestinal permeability in the pathogenesis of the disease
prompted several groups to investigate IEB permeability
in parkinsonian patients. The three studies, which have
been carried out to date have all used absorption of sugar
probes as a means to investigate non-invasively the para-
cellular permeability [12]. These studies, which have in-
cluded a small number of patients, led to conflicting
results. Two studies found a pattern of sugar absorption
reminiscent of small intestine hyperpermeability in a subset
of patients [13,14] while the third one showed an increase
in sucralose excretion without changes in the lactulose/
mannitol ratio, a pattern consistent with increased colonic
permeability [15]. We therefore undertook the present re-
search to analyze in more details the IEB in PD. To this
end, a functional and structural characterization of the IEB
was performed in colonic biopsies from PD patients.
Materials and methods
Subjects
A total of 42 subjects participated in this study, 31 PD
patients and 11 healthy controls. PD patients aged 43–74
years were recruited from the movement disorder clinic at
Nantes University Hospital, France. Diagnosis of PD was
made according to criteria provided by the United King-
dom Parkinson’s Disease Survey Brain Bank [16]. Col-
lected demographic data included gender, age at onset and
disease duration, as well as age at colonoscopy. Complete
drug history was obtained, and an approximation of the
cumulative dose of L-dopa was made based on the equa-
tion developed by Parkkinen and collaborators [17]. Con-
trol subjects were healthy subjects who had a normal
colonoscopy performed for colorectal cancer screening.
All controls subjects underwent a detailed neurological
examination to rule out PD symptoms and cognitive defi-
ciency. Controls and PD patients were excluded if they suf-
fered from irritable bowel syndrome and/or anorectal
dysfunction. The study protocol was approved by the local
Committee on Ethics and Human Research (Comité de
Protection des Personnes Ouest VI) and registered on Clin-
icalTrials.gov (identifier NCT01748409). Written informed
consent was obtained from each patient and from each nor-
mal volunteer according to the principles of Helsinki.
Endoscopic procedure and colonic biopsies
For each subject, nine biopsies were taken in the sigmoid/
descending colon during the course of a rectosigmoido-
scopy for PD patients and during a colonoscopy for con-
trol subjects. Five biopsies were immersed in 4°C Hank’s
Balanced Salt Solution (Life Technologies, Saint Aubin,
France): three of these biopsies were immediately processedfor the assessment of para- and transcellular permeability
in Ussing chambers while the two other biopsies were used
for immunohistochemistry experiments. Two biopsies were
stored at −80°C in lysis buffer RA1 (Macherey-Nagel,
Hoerdt, France) with 1% (v/v) β-mercaptoethanol (Sigma,
Saint Quentin Fallavier, France) for further analysis by
immunoblotting. The two remaining biopsies were
snap frozen in liquid nitrogen at the time of collection
and kept at −80°C.
Para- and transcellular permeability of colonic biopsies in
Ussing chambers
Three biopsies were mounted in Ussing chambers (World
Precision Instruments; WPI, Hertfordshire, UK) exposing
a surface of 0.011 cm2. Tissues were bathed on each side
with 3 ml of F12 supplemented Dulbecco’s Modified Eagle
medium (Invitrogen, France) containing 0.1% (v/v)
fetal bovine serum, 200 mM Glutamine and 45 g/L of
NaHCO3. The medium was continuously oxygenated
and maintained at 37°C by a gas flow (95% O2/5%
CO2). After a 30 min baseline period, 275 μL of apical
medium was replaced with 200 μL of media containing
1 mg/mL of fluorescein-5,6-sulfonic acid (molecular
weight: 400 Da) (Life Technologies) for a final concen-
tration of 0.1 mg/mL to assess paracellular permeabil-
ity. Seventy-five microliters of media with 10 mg/mL
of Horse Radish Peroxydase (HRP) (Sigma) were also
added to the basolateral chamber for a final concentra-
tion of 0.375 mg/mL to measure transcellular perme-
ability in a subset of PD patients and control subjects.
The fluorescence level of basolateral aliquots of 150 μl,
reflecting paracellular transit from the luminal surface
was measured every 30 min over a 3-hour period using a
fluorimeter (Varioskan®, ThermoFisher Scientific, Cillebon
sur Yvette, France). HRP quantities in the basolateral
chamber, reflecting transcellular transit from the apical
surface, was measured using an enzymatic activity assay
with 3,3’,5,5’-tetramethylbenzidine reagent (BD Bioscience,
Le Pont de Claix, France). Paracellular and transcellular
permeabilities were determined by averaging the gradient
of change in fluorescence intensity over time in the three
biopsies that were analyzed per patient, using a linear re-
gression fit model (GraphPad Prism 5, La Jolla, USA).
Western blot
For the analysis of ZO-1 expression, total proteins from
the 2 biopsies stored in RA1 buffer were precipitated
and prepared for Polyacrylamide Gel Electrophoresis
(PAGE) using protein precipitator and resuspension
buffer (Protein solving buffer and (tris(2-carboxyethyl)
phosphine) TCEP reducing agent, PSB/TCEP) from
NucleoSpin Triprep Kit (Macherey-Nagel, Hoerdt, France)
according to the manufacturer’s instructions. For experi-
ments on the transmembrane protein occludin, the two
Table 1 Main clinical characteristics of PD patients
Age Sex Disease duration
(years)
Cumulative lifetime
dose of L-dopa (mg)
1 70 F 2 0
2 64 M NK NK
3 70 M NK NK
4 66 M 23 66111000
5 47 F 2 0
6 62 M 4 3823375
7 74 M 13 1505625
8 53 M 4 2372500
9 69 M 2.5 273750
10 43 F 11 508050
11 67 M 2.3 0
12 58 M 7 2135250
13 58 M 9 1533000
14 72 F 14 1442662.5
15 64 M 4 492750
16 64 M 10 355875
17 56 M NK NK
18 66 M 4.6 0
19 62 M 26 1560375
20 70 F 2.2 219000
21 57 M 1.8 0
22 58 M 13 2007500
23 50 M 8 1286625
24 69 F 28 3759500
25 62 M 8 511000
26 56 F 8 1241000
27 46 M 10 1213625
28 56 F 8.4 866875
29 58 F 4.8 447125
30 54 M 24 3085423
31 58 M 10 3374130
NK: not known.
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buffer (7 M Urea, 2 M Thiourea and 4% CHAPS) containing
a protease inhibitor cocktail (Complete™, Roche, Meylan,
France) using the “Precellys 24” tissue homogenizer
(Bertin technologies, Saint Quentin-en-Yvelines, France)
and followed by sonication with “vibracell 75 186” device
(Sonics, Newton CT, USA). Equal amounts of lysate were
separated using the Invitrogen NuPage Novex 3-8%
Tris-Acetate Midi Protein Gels™ for ZO-1 or NuPage
Novex 4-12% Bis-Tris MidiGels™ for occludin before
electrophoretic transfer to nitrocellulose membranes
with the iBlot™ Dry Blotting System also from Invitro-
gen. Membranes were processed for immunoblotting
using rabbit polyclonal anti-ZO-1 (1:500, Life Technologies)
and rabbit anti-occludin (1:250, Abcam, Paris, France) anti-
bodies and the relevant immunoreactive bands were quan-
tified as previously described [18].
Microdissection and immunohistochemistry
Microdissection was performed as previously described
[19] in two out of the nine biopsies taken per patient. Each
whole-mount preparation of submucosa obtained from a
single biopsy was permeabilized for 3 hours in phosphate
buffered saline (PBS)/NaN3 containing 1% (v/v) Triton
X-100 and 10% (v/v) horse serum and then incubated
with antibodies against phosphorylated alpha-synuclein
(1:5000, WAKO, Osaka, Japan) and PGP9.5 (1:10,000;
Ultraclone Limited, UK). Each whole-mount preparation
of mucosa was treated for 24 h with Scale A2 solution
composed of 4 M urea, 10% (w/v) glycerol and 0.1% (v/v)
Triton X100 [20] then incubated with rabbit polyclonal
antibodies to ZO-1 (1:100, Life Technologies) and occludin
(1:100, Abcam). Suitable secondary antibodies conjugated to
Alexa Fluor 488 and 594 were used (Invitrogen, Cergy-
Pontoise, France). Following incubation with the secondary
antibodies, the mucosa samples were treated for 10 minutes
with a solution of 0.3% (w/v) of Sudan Black B powder
(Sigma) dissolved in 70% (v/v) ethanol, then washed exten-
sively with PBS. Whole specimen of submucosa and mucosa
were viewed under an Axio Zoom.V16 stereomicroscope
(Zeiss, Marly Le Roi, France). All samples were deidentified
and studied in a blinded manner. For the analysis of ZO-1
and occludin immunofluorescence, the percentage of mor-
phologically normal crypts per biopsy was calculated and
the following classification was used: ‘normal’, more than 2/3
of morphologically normal crypts; ‘mild disruption’: between
1/3 and 2/3 of morphologically normal crypts; ‘disrupted’:
less than 1/3 of morphologically normal crypts.
Statistics
All data are given as the mean ± standard error of the
mean (SEM). For comparisons of means between groups,
a Mann–Whitney test was performed. Differences were
deemed statistically significant if p < 0.05.Results
A total of 31 PD patients and 11 controls were included.
Table 1 shows the main clinical and demographic fea-
tures of all patients. Age and sex did not differ sig-
nificantly between PD patients and control subjects
(mean age was 64.2 ± 2.1 for PD and 60.6 ± 1.4 for
controls, p = 0.25; 22/31 male in PD group and 6/11
male in control group, p = 0.13).
Para- and transcellular permeability are unaffected in PD
In a first set of experiments, we evaluated whether IEB
is functionally altered in PD patients. The para- and
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sured in Ussing chambers in both PD patients and con-
trol subjects using sulfonic acid and HRP, respectively.
No difference in the sulfonic acid flux was observed be-
tween PD patients and control subjects (n = 31 and 11,
respectively; p = 0.65) (Figure 1A). HRP flux was also
comparable between PD subjects and healthy controls
(n = 21 and 9, respectively; p = 0.39) (Figure 1B). Although
not statistically different from controls, the sulfonic acid
and HRP flux values were heterogeneous between PD pa-
tients (Figure 1A and B). We thus investigated if the main
clinical features of the disease had any influence on IEBFigure 1 Comparison of para- and transcellular permeability
in PD patients and healthy controls. (A) For the evaluation of
paracellular permeability, the flux of sulfonic acid (SA flux) was
measured in colonic biopsies mounted in Ussing chambers,
expressed in arbitrary units (AU), in PD patients (n = 31) and
controls (CTRL, n = 11). No significant changes were observed
between the two groups (p = 0.65). (B) For the evaluation of
paracellular permeability, the flux of horseradish peroxidase
(HRP flux) was measured in colonic biopsies mounted in Ussing
chambers, expressed in ng/mL/min, in PD patients (n = 21) and
controls (CTRL, n = 9). No significant changes were observed
between the two groups (p = 0.39).permeability. We did not observe any correlation between
age, disease duration or lifetime cumulative dose of L-
DOPA and the values of sulfonic acid or HRP flux
(Table 2).
There is a growing body of evidence supporting a key
role for submucosal enteric neurons in the regulation of
IEB functions [21-23]. This prompted us to study if the
flux values of sulfonic acid and HRP were related to the
presence of Lewy bodies and Lewy neurites in the sub-
mucosa. To this end, two biopsies per patient were
immunohistochemically assessed for the presence of
Lewy pathology using antibodies against phosphorylated
alpha-synuclein and PGP9.5 (Figure 2A and B). A biopsy
was deemed positive when containing at least one inclu-
sion immunoreactive for both phosphorylated alpha-
synuclein and PGP9.5 (Figure 2C). A patient was noted
as positive when at least one of the two biopsies dis-
played inclusion(s). In accordance with our previous
reports [24,25], the intraneuronal inclusions found in
the submucosal plexus were chiefly observed in the
neuronal processes and thus reminiscent of Lewy neur-
ites (Figure 2A-C). Twenty-three out of 31 PD patients
were positive for phosphorylated alpha-synuclein inclu-
sions. All control subjects were devoid of inclusions.
The values of sulfonic acid and HRP flux were not dif-
ferent between PD patients with or without inclusions
(Figure 2D and E).
Expression of the tight junction protein occludin is
decreased in PD
We next investigated whether structural changes in the
IEB occur in PD. The expression levels of the TJs pro-
teins ZO-1 and occludin were analyzed by Western blot
in colonic biopsies from PD subjects and healthy con-
trols. A significant decrease in the expression of occlu-
din was observed in colonic samples of PD patients as
compared to controls (Figure 3A and B). A doublet band
of approximately 220 kDa was observed on Western blot
with antibodies against ZO-1 (Figure 3A). As previously
shown, these two bands most likely represent the two
ZO-1 isoforms [26,27]. By contrast to occludin, no change
in ZO-1 expression levels was observed in PD whether the
two bands were quantified together (Figure 3C) or separ-
ately (data not shown).Table 2 Spearman’s correlation with sulfonic acid (SA)





SA p = 0.090 p = 0.788 p = 0.830
r = 0.303 r = 0.052 r = −0.046
HRP p = 0.165 p = 0.469 p = 0.754
r = 0.323 r = 0.172 r = 0.082
Figure 2 Sulfonic acid and HRP flux in PD in patients with and without enteric Lewy pathology. Representative photomicrograph
depicting multiple Lewy neurites in a whole-mount of submucosa immunoreactive for PGP9.5 (A) that was also positive for phosphorylated
alpha-synuclein (B and C) Scale bar: 200 μm. (D) The values of sulfonic acid flux was not different between PD patients with (PS+) or without
(PS-) phospho-synuclein immunoreactive neurites (p = 0.93). (E) The values of HRP flux was not different between PD patients with (PS+) or
without (PS-) phospho-synuclein immunoreactive neurites (p = 0.46).
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The cellular distribution of occludin and ZO-1 was fur-
ther investigated by immunofluorescence in 8 controls
and 31 PD subjects. Samples from 3 controls were ex-
cluded because the mucosa was too small and/or too
damaged to allow a reliable analysis of the TJs morph-
ology. A mean of 96.4 crypts per biopsy were analyzed.
We observed differences in the cellular distribution of
both ZO-1 and occludin between PD patients andcontrols (Figure 4). A normal and typical reticular pat-
tern of occludin and ZO-1 staining was observed in the
colonic samples of 6 out of 8 controls (Figure 4A and C,
Additional file 1) and in only 9/31 PD patients (Figure 4B
and D, Additional file 1). TJs morphology was disrupted
and irregularly distributed in the mucosa of 1 out of 8
controls (Figure 4A and C, Additional file 1) and in 14/
31 PD patients (Figure 4B and D, Additional file 1). An
occasional and mild disruption of TJs morphology was
Figure 3 Expression of TJs proteins in colonic biopsies from patients with Parkinson’s disease (PD) and control subjects (CTRL). Biopsies
lysates (20 μg of protein per sample) were subjected to immunoblot analysis using antibodies against occludin and ZO-1 (A). Beta-actin was used
as a loading control. The optical densities of occludin (B) and ZO-1 (C) immunoreactive bands were measured, normalized to the optical densities
of beta-actin immunoreactive bands in the same samples and expressed as percentages of controls. Data correspond to mean ± SEM of 11
samples for control subjects (CTRL) and 31 samples for Parkinson’s disease (PD) patients. Patients versus control, *: p < 0.05.
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PD samples (Figure 4 and Additional file 1). An in-
creased staining of occludin in the cytoplasm of colonic
enterocytes, suggestive of protein internalization, was
observed in PD samples as opposed to the healthy group
where occludin was mostly located in the TJs (Figure 4C
and D). Worthy of note was the presence of moderate to
severe TJs disorganization in the 5 patients who had
never received levodopa, suggesting that the altered TJs
morphology was not related to chronic levodopa intake
(Additional file 2 and Table 1).
Discussion
The TJs are intercellular protein complex located at the
apical portions of the lateral membranes of epithelial
cells which play a key role in the regulation of IEB para-
cellular permeability. They are composed of transmem-
brane proteins, such as claudins and occludin and a
wide spectrum of cytosolic proteins among which is ZO-1
[1]. By showing a decrease in occludin expression
along with TJs disorganization, our study is the first toprovide evidence that the IEB is structurally altered in
PD. Previous studies have shown intestinal tissue expres-
sion and distribution of occludin to be markedly de-
creased in patients with intestinal permeability disorders,
including inflammatory bowel disease [28] and irritable
bowel syndrome [6]. Recent data from genetic and epi-
demiological studies provided support for an association
between diseases of the gastrointestinal tract and the sus-
ceptibility to developing PD. The CARD15 gene known to
be associated with Crohn's disease is over-represented in
patients with PD [29]; vice versa, the Leucine-rich repeat
kinase 2 (LRRK2) gene, a causative PD mutation, was re-
cently identified as a major susceptibility gene for Crohn’s
disease by genome-wide association studies [30]. More-
over, patients with irritable bowel syndrome are almost
50% more likely to develop PD than people who are free
of this gastrointestinal disorder [31]. Our results show that
the two disorders also share similarities at the molecular
levels further supporting the assumption that irritable
bowel syndrome may actually belong to early signs of
gastrointestinal involvement in PD [32]. They also support
Figure 4 Localization of TJs proteins in the colonic mucosa of healthy controls (CTRL) and patients with Parkinson’s disease (PD).
Representative photomicrographs of the colonic mucosa labeled with antibodies against ZO-1 (A, B) and occludin (C, D) in the colonic mucosa
of control and PD patients; scale bar: 100 μm. High-magnification image of each area marked by red square; scale bar: 10 μm.
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involved in the pathophysiology of both disorders [7,33].
Studies of intestinal permeability in humans have
mainly been carried out with in vivo techniques, usually
with oral ingestion of various sugar probes and measure-
ment of urinary excretion [12]. To date, the three studies
that attempted to evaluate intestinal permeability in PD
using this technique have provided only preliminary and
conflicting results. Two of these studies focused on the
lactulose/mannitol ratio, which evaluate small intestinal
permeability. As a group, the 15 PD patients studied by
Davies and collaborators had a significant increase in the
lactulose/mannitol ratio when compared to age and sex
matched controls, but individual results in both groups
were highly overlapping [14]. Salat-Foix et al. showed
that the lactulose/mannitol ratio was only marginally
higher in 3 out of 12 PD patients [13]. In addition to lac-
tulose/mannitol ratio, Forsyth et al. also used sucralose
absorption for the assessment of colon permeability in 9
PD patients and 10 controls. They did not observe any
difference in the lactulose/mannitol ratio between the
two groups but found a significantly greater permeability
to sucralose in PD subjects [15]. The inconsistent results
on intestinal permeability in PD obtained with sugar
probes prompted us to measure IEB permeability by an-
other technique, namely Ussing chambers, in a larger
sample size. Although less commonly used than sugar
absorption, the Ussing chambers has proven to be a reli-
able and effective tool to measure IEB permeability ofgastrointestinal biopsies either paracellularly or transcel-
lularly over a 3 hour period [34]. Using this approach,
we showed that there were no significant differences in
para- and transcellular permeabilities between PD sub-
jects and controls. Nevertheless, the values of para-
cellular permeability as assessed by the sulfonic acid
flux in Ussing chamber were highly heterogeneous be-
tween PD patients, some displaying a level comparable
to controls while others had a more than a 2.5 fold
increase in sulfonic acid flux. These data suggest that
increased colonic permeability may be a feature for a
subset of PD patients, as already reported when sugar
probes were used [15]. The factors responsible for this
heterogeneity still remain to be determined, as we did
not observe any correlation between age, cumulative
dose of L-Dopa disease duration and the severity of al-
tered permeability.
On the surface, our results may seem contradictory, as
the decreased expression of occludin observed in PD pa-
tients was not accompanied by changes in paracellular
permeability. Occludin is a tetraspan protein with two
extracellular loops, which homophilically interact with
the adjacent cells [2]. Its role on IEB has been debated
since its initial discovery in 1993 [35]. Initial studies
strongly suggested that occludin was not required for
the TJs formation or the maintenance of barrier function
as occludin knockout mice lacked any noticeable defect
in intestinal TJs morphology or barrier function [36].
This has been recently challenged in an elegant study
Clairembault et al. Acta Neuropathologica Communications  (2015) 3:12 Page 8 of 9published by Al-Sadi et al. [37]. The purpose of their re-
search was to better delineate the involvement of occlu-
din in IEB by studying the transepithelial flux of
various-sized probes after knocking down occludin both
in vitro and in vivo. They showed that the occludin
knock down caused a marked increase in the flux rates
of macromolecules above 5 kDa such as inulin and dex-
tran but had only modest effect on flux of smaller-sized
probes under 200 Da such as mannitol and urea [36].
Fluorescein-5,6-sulfonic acid, which was used for the as-
sessment of paracellular permeability in our study has a
molecular weight of 400 Da, likely to be too small for
detecting defects in IEB permeability induced by a mere
down regulation of occludin. This may explain the lack
of significant changes in IEB permeability observed in
PD patients in our study in spite of the occurrence of
structural changes.
The question arises as to what might be the clinical
relevance of our experimental findings. A current theory,
the so-called Braak’s theory, assumes that PD originates
in the gastrointestinal tract [11]. Braak and co-workers
suggested that the appearance of Lewy pathology occurs
in the earliest stage of PD in both the enteric nervous
system and the dorsal motor nucleus of the vagus
[11,38]. This led Braak to postulate that a pathogen may
breach the IEB to trigger Lewy pathology in the terminal
axons of the enteric neurons, further spreading to the
central nervous system via the vagal preganglionic in-
nervation of the gut [11,39]. In light of these consider-
ations, our results demonstrating altered intestinal TJs
structure in PD gain in importance as the down regula-
tion of occludin may favor the entry of a putative patho-
gen. This must be however balanced, as the stomach in
contrast to the colon appears to be the most suitable tar-
get for the pathologic insult to occur in Braak’s scenario.
Several studies have indeed described that Lewy path-
ology is distributed following a rostro-caudal gradient in
PD, with the lower esophagus and stomach having the
greatest involvement and the colon and rectum the low-
est [9,10], a distribution that parallels the vagal innerv-
ation of the gastrointestinal tract [40]. Further studies
are therefore warranted to analyze the mucosal barrier
permeability and morphology in gastric and duodenal
samples from PD patients.
Conclusions
In conclusion, we provide evidence for the first time that
morphological changes in the IEB occur in PD patients.
Our results further reinforce the possible role of the
gastrointestinal tract in the pathophysiology of PD.
Further work is needed to determine if occludin down
regulation in the gut might facilitate the spreading of PD
pathology in the enteric nervous system and in the
brain.Additional files
Additional file 1: Percentage of morphologically normal crypts in
the colonic mucosa of healthy controls (CTRL) and patients with
Parkinson’s disease (PD).
Additional file 2: Localization of TJs proteins in the colonic mucosa
of the 5 with Parkinson’s disease (PD) who had never received
levodopa. Scale bar: 100 μm.
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